Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

882155

	registered interest
	date	13/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Pharmaceutical Price Regulation Scheme
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the timetable for negotiations on the new pharmaceutical price regulation scheme is; and if he will make a statement.
	tabling member constituency	Stafford
	tabling member printed	Jeremy Lefroy
	uin	135214
	answer	answer is ministerial correction date of answer 19/04/2018 answer text <p>Informal discussions have already begun with industry regarding future medicines pricing arrangements. Formal negotiations will begin shortly.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 19/04/2018 11:28:11 answering member 4067 label Biography information for Steve Brine
	tabling member	4109 label Biography information for Jeremy Lefroy

882668

	registered interest
	date	13/04/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Rare Diseases
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Government plans to continue to participate in the European Reference Networks for patients with complex or rare medical conditions after the UK leaves the EU and the expiry of the implementation period.
	tabling member constituency	Stafford
	tabling member printed	Jeremy Lefroy
	uin	135730
	answer	answer is ministerial correction date of answer 19/04/2018 answer text <p>The Government has noted the importance of continued collaboration with European partners in the 2017 policy paper ‘Collaboration on Science and Innovation: A Future Partnership Paper’. European Reference Networks (ERNs) for rare diseases patients were cited in the paper as an example of collaboration that the United Kingdom and European Union should discuss in the negotiations, given the mutual benefit.</p><p> </p><p>The Government has set out three key principles in developing a new regulatory system post EU exit: patients should not be disadvantaged; innovators should be able to get their products into the UK market as quickly and simply as possible; and we continue to play a leading role promoting public health. The Government will be guided by these principles in its negotiations with EU partners.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 19/04/2018 14:12:32 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	4109 label Biography information for Jeremy Lefroy